<ul>
<li>MarketBeat 评选的五大高评级小型股</li>
</ul>
<p>Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免费报告）- HC Wainwright 的股票研究人员在 5 月 6 日向客户和投资者发布的研究报告中下调了对 Trevi Therapeutics 的 2030 财年收益预期。HC Wainwright 分析师 B. Folkes 现在预测该公司将发布每股收益 0.70 美元，低于之前预测的 0.79 美元。HC Wainwright 目前对该股票的评级为 “买入”，目标价格为 21.00 美元。市场普遍预期 Trevi Therapeutics 当前全年的收益为每股（0.46）美元。</p>
<p>获取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
<p>其他股票分析师最近也对该公司发布了报告。摩根士丹利在周三的研究报告中重申了对 Trevi Therapeutics 的 “增持” 评级，并给出了 20.00 美元的目标价格。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Trevi Therapeutics 的 “卖出（d-）” 评级。Needham &amp; Company LLC 在周三的研究报告中将 Trevi Therapeutics 的目标价格从 24.00 美元下调至 23.00 美元，并对该股票给予 “买入” 评级。JonesTrading 在 3 月 19 日的研究报告中将 Trevi Therapeutics 的目标价格从 25.00 美元下调至 24.00 美元，并对该股票给予 “买入” 评级。最后，D. Boral Capital 在 4 月 17 日的研究报告中重申了 “买入” 评级，并给出了 19.00 美元的目标价格。两位分析师对该股票给予了强烈买入评级，九位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “买入”，共识目标价格为 21.70 美元。</p>
<p><strong>查看我们关于 Trevi Therapeutics 的最新股票报告</strong></p>
<h2>Trevi Therapeutics 股票下跌 2.7%</h2>
<p>周四，TRVI 股票开盘价为 14.26 美元。该公司的 50 日移动平均价格为 12.63 美元，200 日移动平均价格为 11.92 美元。该公司的市值为 18.3 亿美元，市盈率为-44.56，贝塔值为 1.07。Trevi Therapeutics 的 52 周低点为 5.38 美元，52 周高点为 16.12 美元。</p>
<p>Trevi Therapeutics（NASDAQ:TRVI - 获取免费报告）最近在 5 月 5 日宣布了其季度收益结果。该公司报告季度每股收益（0.09）美元，低于分析师的共识预期（0.07）美元，差距为（0.02）美元。</p>
<h2>对 Trevi Therapeutics 的对冲基金看法</h2>
<p>一些机构投资者最近买入和卖出了该股票的股份。中国环球资产管理有限公司在第三季度将其在 Trevi Therapeutics 的持股增加了 4.5%。中国环球资产管理有限公司现在拥有 21,346 股该公司的股票，价值 195,000 美元，在此期间又购买了 911 股。Hilton Head Capital Partners LLC 在第一季度将其在 Trevi Therapeutics 的持股增加了 32.6%。Hilton Head Capital Partners LLC 现在拥有 4,250 股该公司的股票，价值 51,000 美元，在此期间又购买了 1,044 股。Ameritas Investment Partners Inc.在第三季度将其在 Trevi Therapeutics 的持股增加了 20.5%。Ameritas Investment Partners Inc.现在拥有 7,632 股该公司的股票，价值 70,000 美元，在此期间又购买了 1,300 股。Kennedy Capital Management LLC 在第四季度将其在 Trevi Therapeutics 的持股增加了 2.4%。Kennedy Capital Management LLC 现在拥有 56,269 股该公司的股票，价值 704,000 美元，在此期间又购买了 1,336 股。最后，未来资产全球投资有限公司在第四季度将其在 Trevi Therapeutics 的持股增加了 32.3%。未来资产全球投资有限公司现在拥有 6,231 股该公司的股票，价值 78,000 美元，在此期间又购买了 1,523 股。95.76% 的股票由机构投资者持有。</p>
<h2>关于 Trevi Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Trevi Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发新型非阿片类疗法以管理慢性和急性疼痛。该公司利用专有药物递送平台和靶向分子方法来解决癌症相关疼痛、化疗引起的神经病和其他严重疼痛状况中的高未满足需求。</p>
<p>其主要产品候选药物是一种专有的河豚毒素（TTX）配方，这是一种钠通道阻滞剂，正在早期临床试验中评估用于与晚期癌症和外周神经病相关的中度至重度疼痛。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Trevi Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Trevi Therapeutics 吗？</h2>
<p>在考虑 Trevi Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Trevi Therapeutics 并不在名单上。</p>
<p>虽然 Trevi Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TRVI

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

DWA 医疗保健动量 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

医药 3 倍做多 - Direxion

医疗业 ETF - SPDR

<p>HC Wainwright 的股票研究员将 Trevi Therapeutics (NASDAQ:TRVI) 的 2030 财年每股收益预期从 0.79 美元下调至 0.70 美元。该公司维持 “买入” 评级，目标价为 21.00 美元。其他分析师的看法各异，摩根士丹利和 Needham & Company 也给予买入评级，但目标价不同。Trevi 的股票最近下跌了 2.7%，开盘价为 14.26 美元，市值为 18.3 亿美元。该公司专注于开发非阿片类的疼痛管理疗法</p>

<ul>
<li>MarketBeat’s Top 5 Rated Small-Cap Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 评选的五大高评级小型股</li>
</ul>
</div><p>Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at HC Wainwright decreased their FY2030 earnings estimates for Trevi Therapeutics in a research report issued to clients and investors on Wednesday, May 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.70 per share for the year, down from their prior forecast of $0.79. HC Wainwright currently has a &#34;Buy&#34; rating and a $21.00 target price on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.46) per share.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc.（NASDAQ:TRVI - 免费报告）- HC Wainwright 的股票研究人员在 5 月 6 日向客户和投资者发布的研究报告中下调了对 Trevi Therapeutics 的 2030 财年收益预期。HC Wainwright 分析师 B. Folkes 现在预测该公司将发布每股收益 0.70 美元，低于之前预测的 0.79 美元。HC Wainwright 目前对该股票的评级为 “买入”，目标价格为 21.00 美元。市场普遍预期 Trevi Therapeutics 当前全年的收益为每股（0.46）美元。</p>
</div><p>Get <strong>Trevi Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Trevi Therapeutics</strong> 的提醒：</p>
</div><p>Other equities analysts also recently issued reports about the company. Morgan Stanley restated an &#34;overweight&#34; rating and issued a $20.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Trevi Therapeutics in a research note on Monday, April 20th. Needham &amp; Company LLC dropped their price target on Trevi Therapeutics from $24.00 to $23.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday. JonesTrading dropped their price target on Trevi Therapeutics from $25.00 to $24.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, March 19th. Finally, D. Boral Capital restated a &#34;buy&#34; rating and issued a $19.00 price target on shares of Trevi Therapeutics in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Buy&#34; and a consensus target price of $21.70.</p>
<div class="lb-trans"><p>其他股票分析师最近也对该公司发布了报告。摩根士丹利在周三的研究报告中重申了对 Trevi Therapeutics 的 “增持” 评级，并给出了 20.00 美元的目标价格。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 Trevi Therapeutics 的 “卖出（d-）” 评级。Needham &amp; Company LLC 在周三的研究报告中将 Trevi Therapeutics 的目标价格从 24.00 美元下调至 23.00 美元，并对该股票给予 “买入” 评级。JonesTrading 在 3 月 19 日的研究报告中将 Trevi Therapeutics 的目标价格从 25.00 美元下调至 24.00 美元，并对该股票给予 “买入” 评级。最后，D. Boral Capital 在 4 月 17 日的研究报告中重申了 “买入” 评级，并给出了 19.00 美元的目标价格。两位分析师对该股票给予了强烈买入评级，九位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “买入”，共识目标价格为 21.70 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Trevi Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Trevi Therapeutics 的最新股票报告</strong></p>
</div><h2>Trevi Therapeutics Stock Down 2.7%</h2>
<div class="lb-trans"><h2>Trevi Therapeutics 股票下跌 2.7%</h2>
</div><p>Shares of TRVI stock opened at $14.26 on Thursday. The company has a 50 day moving average price of $12.63 and a 200-day moving average price of $11.92. The firm has a market capitalization of $1.83 billion, a PE ratio of -44.56 and a beta of 1.07. Trevi Therapeutics has a 52 week low of $5.38 and a 52 week high of $16.12.</p>
<div class="lb-trans"><p>周四，TRVI 股票开盘价为 14.26 美元。该公司的 50 日移动平均价格为 12.63 美元，200 日移动平均价格为 11.92 美元。该公司的市值为 18.3 亿美元，市盈率为-44.56，贝塔值为 1.07。Trevi Therapeutics 的 52 周低点为 5.38 美元，52 周高点为 16.12 美元。</p>
</div><p>Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.02).</p>
<div class="lb-trans"><p>Trevi Therapeutics（NASDAQ:TRVI - 获取免费报告）最近在 5 月 5 日宣布了其季度收益结果。该公司报告季度每股收益（0.09）美元，低于分析师的共识预期（0.07）美元，差距为（0.02）美元。</p>
</div><h2>Hedge Funds Weigh In On Trevi Therapeutics</h2>
<div class="lb-trans"><h2>对 Trevi Therapeutics 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company's stock worth $195,000 after purchasing an additional 911 shares during the period. Hilton Head Capital Partners LLC raised its holdings in Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company's stock worth $51,000 after purchasing an additional 1,044 shares during the period. Ameritas Investment Partners Inc. raised its holdings in Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company's stock worth $70,000 after purchasing an additional 1,300 shares during the period. Kennedy Capital Management LLC raised its holdings in Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company's stock valued at $704,000 after acquiring an additional 1,336 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company's stock valued at $78,000 after acquiring an additional 1,523 shares during the period. 95.76% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了该股票的股份。中国环球资产管理有限公司在第三季度将其在 Trevi Therapeutics 的持股增加了 4.5%。中国环球资产管理有限公司现在拥有 21,346 股该公司的股票，价值 195,000 美元，在此期间又购买了 911 股。Hilton Head Capital Partners LLC 在第一季度将其在 Trevi Therapeutics 的持股增加了 32.6%。Hilton Head Capital Partners LLC 现在拥有 4,250 股该公司的股票，价值 51,000 美元，在此期间又购买了 1,044 股。Ameritas Investment Partners Inc.在第三季度将其在 Trevi Therapeutics 的持股增加了 20.5%。Ameritas Investment Partners Inc.现在拥有 7,632 股该公司的股票，价值 70,000 美元，在此期间又购买了 1,300 股。Kennedy Capital Management LLC 在第四季度将其在 Trevi Therapeutics 的持股增加了 2.4%。Kennedy Capital Management LLC 现在拥有 56,269 股该公司的股票，价值 704,000 美元，在此期间又购买了 1,336 股。最后，未来资产全球投资有限公司在第四季度将其在 Trevi Therapeutics 的持股增加了 32.3%。未来资产全球投资有限公司现在拥有 6,231 股该公司的股票，价值 78,000 美元，在此期间又购买了 1,523 股。95.76% 的股票由机构投资者持有。</p>
</div><h2>About Trevi Therapeutics</h2>
<div class="lb-trans"><h2>关于 Trevi Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.</p>
<div class="lb-trans"><p>Trevi Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发新型非阿片类疗法以管理慢性和急性疼痛。该公司利用专有药物递送平台和靶向分子方法来解决癌症相关疼痛、化疗引起的神经病和其他严重疼痛状况中的高未满足需求。</p>
</div><p>Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.</p>
<div class="lb-trans"><p>其主要产品候选药物是一种专有的河豚毒素（TTX）配方，这是一种钠通道阻滞剂，正在早期临床试验中评估用于与晚期癌症和外周神经病相关的中度至重度疼痛。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Trevi Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Trevi Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=TRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Trevi Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Trevi Therapeutics 吗？</h2>
</div><p>Before you consider Trevi Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Trevi Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Trevi Therapeutics 并不在名单上。</p>
</div><p>While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Trevi Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Research Analysts Set Expectations for TRVI FY2030 Earnings

Market Beat

Trevi Therapeutics

摩根士丹利

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

Weis Markets

卡尔蔡司

NEUBERGER BERMAN REAL ES-W/I

Landbridge Co LLC

Chemours

New England Real Asso

Jewett-Cameron

TJX零售

TJGC

D. BORAL ARC ACQUISITION I CORP. C/WTS 23/07/2030(TO PUR COM)

D Boral ARC Acquisition I

D Boral ARC Acquisition I - Unit

中国光大控股

Arcadian Asset

SC ASSETS HLDGS - D

Rit Capital Partners PLC

Hennessy Capital Investment Corp VII

Hennessy Capital Investment Corp VII - Unit

Virtus投资

Artisan合伙资产管理

VGI Partners Global Investments Ltd.

Kennedy-Wilson控股

Annaly资本管理

Sun Capital Management Corp.

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

中国光大水务

光大永年

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

研究分析师设定了对 Trevi Therapeutics 2030 财年收益的预期